About Toll/interleukin-1 receptor domain-containing adapter protein
Toll/interleukin-1 receptor domain-containing adapter protein (TIRAP) is a protein
from Homo sapiens identified by UniProt accession
P58753, 221 residues long.
MolForge cross-references it against 0 known binders and
175 disease associations.
Target properties
| Protein name | Toll/interleukin-1 receptor domain-containing adapter protein |
|---|
| UniProt accession | P58753 |
|---|
| Gene | TIRAP |
|---|
| Organism | Homo sapiens |
|---|
| Length | 221 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (175)
Diseases linked to this target (Open Targets).
- inborn error of immunity · score 0.37
- mean platelet volume · score 0.28
- neurodegenerative disease · score 0.23
- appendicular lean mass · score 0.22
- neutrophil percentage of granulocytes · score 0.19
- eosinophil percentage of leukocytes · score 0.19
- cutaneous melanoma · score 0.17
- eosinophil percentage of granulocytes · score 0.17
- body height · score 0.16
- eosinophil count · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P58753-F1 | alphafold | PREDICTED | 73.97 | — |
Amino-acid sequence (221 residues)
MASSTSLPAP GSRPKKPLGK MADWFRQTLL KKPKKRPNSP ESTSSDASQP TSQDSPLPPS LSSVTSPSLP PTHASDSGSS RWSKDYDVCV CHSEEDLVAA QDLVSYLEGS TASLRCFLQL RDATPGGAIV SELCQALSSS HCRVLLITPG FLQDPWCKYQ MLQALTEAPG AEGCTIPLLS GLSRAAYPPE LRFMYYVDGR GPDGGFRQVK EAVMRYLQTL S
Explore Toll/interleukin-1 receptor domain-containing adapter protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets